Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Agrippal 2015 Southern Hemisphere Formulation in Healthy Adults
NCT02427750Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of subunit inactivated influenza vaccine in influenza, sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
subunit inactivated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02427750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427750.